Drugs / rTSST-1 Variant Candidate Vaccine
rTSST-1 Variant Candidate Vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02971670 | Oct 2015 → Mar 2016 | infectious disease with sepsis, toxic shock syndrome | Biomedizinische Forschungs gmbH | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | rTSST-1 Variant Candidate Vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02971670 ↗ |
| Known as | BioMed recombinant toxic shock syndrome toxin (rTSST-1) Variant Vaccine | “The Phase I study BioMed0713 demonstrated the safety and tolerability of the BioMed recombinant toxic shock syndrome toxin (rTSST-1) Variant Vaccine in healthy adults.” NCT02971670 ↗ |
| Known as | BioMed rTSST-1 Variant Vaccine | “The aim of this amendment is to demonstrate prolonged safety of the BioMed rTSST-1 Variant Vaccine and to assess persistence of antibodies generated in participants.” NCT02971670 ↗ |
| Known as | rTSST1 Variant Vaccine | “This is a prospective, single-blinded follow-up study of the safety and immunogenicity of the BioMed rTSST1 Variant Vaccine compared to adjuvant in healthy adults.” NCT02971670 ↗ |
| Modality | Vaccine | “The BioMed rTSST-1 Variant Vaccine has been developed by Biomedizinische ForschungsgmbH as one component of a polyvalent staphylococcal vaccine” NCT02971670 ↗ |